BR112015023209A2 - novos medicamentos compreendendo uma composição de anticorpo enrriquecida com uma carga principal de isoforma - Google Patents

novos medicamentos compreendendo uma composição de anticorpo enrriquecida com uma carga principal de isoforma

Info

Publication number
BR112015023209A2
BR112015023209A2 BR112015023209A BR112015023209A BR112015023209A2 BR 112015023209 A2 BR112015023209 A2 BR 112015023209A2 BR 112015023209 A BR112015023209 A BR 112015023209A BR 112015023209 A BR112015023209 A BR 112015023209A BR 112015023209 A2 BR112015023209 A2 BR 112015023209A2
Authority
BR
Brazil
Prior art keywords
antibody composition
loading
enriched
major isoform
composition
Prior art date
Application number
BR112015023209A
Other languages
English (en)
Other versions
BR112015023209A8 (pt
Inventor
Chevreux Guillaume
Bihoreau Nicolas
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of BR112015023209A2 publication Critical patent/BR112015023209A2/pt
Publication of BR112015023209A8 publication Critical patent/BR112015023209A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Abstract

resumo da patente de invenã§ã£o para: “novos medicamentos compreendendo uma composiã‡ãƒo de anticorpo enrriquecida com uma carga principal de isoforma”. a presente invenã§ã£o situa-se no campo tã©cnico das terapias de anticorpos envolvendo um mecanismo de destruiã§ã£o pelo ccad. estã¡ relacionado a composiã§ãµes de anticorpos purificadas, obtidas pelo fracionamento cromatogrã¡fico de vã¡rias cargas de isoforma naturalmente presentes em uma composiã§ã£o de anticorpo e combinando uma ou mais fraã§ãµes cromatogrã¡ficas correspondendo ao pico predominante do cromatograma, a composiã§ã£o de anticorpo monoclonal resultante sendo enriquecida no dito pico predominante, o dito pico predominante representando pelo menos 85% do cromatograma da composiã§ã£o obtida, para uso como um medicamento.
BR112015023209A 2013-03-15 2014-03-14 novos medicamentos compreendendo uma composição de anticorpo enriquecida com uma carga principal de isoforma BR112015023209A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1352360A FR3003171B1 (fr) 2013-03-15 2013-03-15 Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
PCT/EP2014/055179 WO2014140322A1 (fr) 2013-03-15 2014-03-14 Nouveaux médicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire

Publications (2)

Publication Number Publication Date
BR112015023209A2 true BR112015023209A2 (pt) 2017-07-18
BR112015023209A8 BR112015023209A8 (pt) 2018-01-23

Family

ID=48771615

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023209A BR112015023209A8 (pt) 2013-03-15 2014-03-14 novos medicamentos compreendendo uma composição de anticorpo enriquecida com uma carga principal de isoforma

Country Status (11)

Country Link
US (1) US20160046722A1 (pt)
EP (1) EP2968533A1 (pt)
JP (1) JP2016512216A (pt)
KR (1) KR20150132522A (pt)
CN (1) CN105163758B (pt)
AU (1) AU2014230134A1 (pt)
BR (1) BR112015023209A8 (pt)
CA (1) CA2907358A1 (pt)
FR (1) FR3003171B1 (pt)
MX (1) MX2015012812A (pt)
WO (1) WO2014140322A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323081B2 (en) * 2011-07-06 2019-06-18 Genmag A/S Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains
WO2017192093A1 (en) 2016-05-04 2017-11-09 Delaval Holding Ab A cartridge for a teatcup, and a teatcup
FR3053688A1 (fr) 2016-07-06 2018-01-12 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Mutants fc a activite fonctionnelle amelioree
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
AU2020211728A1 (en) 2019-01-23 2021-08-12 Encefa CD31 competitors and uses thereof
CN113874720A (zh) * 2019-05-23 2021-12-31 瑞泽恩制药公司 抗体结构域特异性电荷变异体的表征分析
CN114829407A (zh) * 2019-09-23 2022-07-29 南开大学 利用哺乳动物展示筛选FcγR特异性结合Fc
WO2023041717A1 (en) 2021-09-16 2023-03-23 Aboleris Pharma Anti-human cd45rc binding domains and uses thereof
CN114236010A (zh) * 2021-12-18 2022-03-25 苏州莱奥生物技术有限公司 一种生物活性药物的药代动力学分析方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0104865A3 (en) * 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
FR2844513B1 (fr) * 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
BRPI0314814C1 (pt) * 2002-09-27 2021-07-27 Xencor Inc anticorpo compreendendo uma variante de fc
SI1558648T1 (sl) * 2002-10-17 2012-05-31 Genmab As Človeška monoklonalna protitelesa proti CD
EP2368578A1 (en) * 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
FR2861078B1 (fr) * 2003-10-16 2007-09-21 Lab Francais Du Fractionnement NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE
SG10201912554TA (en) * 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
US10323081B2 (en) * 2011-07-06 2019-06-18 Genmag A/S Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains

Also Published As

Publication number Publication date
MX2015012812A (es) 2016-05-09
CA2907358A1 (fr) 2014-09-18
BR112015023209A8 (pt) 2018-01-23
JP2016512216A (ja) 2016-04-25
CN105163758A (zh) 2015-12-16
EP2968533A1 (fr) 2016-01-20
KR20150132522A (ko) 2015-11-25
AU2014230134A1 (en) 2015-10-29
US20160046722A1 (en) 2016-02-18
CN105163758B (zh) 2017-11-17
FR3003171A1 (fr) 2014-09-19
FR3003171B1 (fr) 2015-04-10
WO2014140322A1 (fr) 2014-09-18

Similar Documents

Publication Publication Date Title
BR112015023209A2 (pt) novos medicamentos compreendendo uma composição de anticorpo enrriquecida com uma carga principal de isoforma
CL2017001364A1 (es) Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos.
BR112015023520A2 (pt) purificação do conjugado de anticorpo-fármaco (adc)
BR112015011403A2 (pt) uso de akkermansia para o tratamento de distúrbios metabólicos
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
BR112015027319A8 (pt) Métodos e composições para modular a expressão de apolipoproteína (a)
BR112012001984B8 (pt) anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica
BR112015021665A2 (pt) misturas de isômeros de (metilciclohe-xil)tolueno, sua produção e uso na fabricação de plastificantes
BR112017016636A2 (pt) formulação líquida estável para anticorpos monoclonais
BR112015027288A8 (pt) uso de uma dose de imunossupressor, composição de nanocarreadores sintéticos tolerogênicos e kit
BR112015019657A2 (pt) composições tópicas e métodos de uso das mesmas
BR112015030595A2 (pt) moduladores de receptor de estrogênio de azetidina e usos dos mesmos
BR112016003229A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
BR112015022566A2 (pt) composto e composição farmacêutica
BR112015005048A8 (pt) métodos para tratar dermatite atópica por administração de antagonista il-4r
CL2015002940A1 (es) Usos terapéuticos de empaglifozina.
BR112016001114A2 (pt) membros da família tnf direcionados modificados
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR112016001446A8 (pt) composições terapêuticas, produto de combinação, uso in vitro de flecainida e flecainida
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112018006368A2 (pt) composição para desempenho melhorado
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
BR112015004875A2 (pt) formulações de anticorpo e seus usos
BR112012023660A2 (pt) novos métodos para direcionar células-tronco cancerosas
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements